PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26399195-10	2016	Importantly, bosentan significantly reversed circulating EPCR and PIC levels in patients with SSc, and the expression of Fli1 and EPCR in dermal small vessels was elevated in patients treated with bosentan compared with untreated patients.	Bosentan	197-205	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	121-125	
26055516-6	2015	Importantly, bosentan, a dual endothelin receptor antagonist with a potential disease-modifying effect on SSc vasculopathy, reverses the expression of Fli1 protein by increasing its protein stability.	Bosentan	13-21	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	151-155	
25707716-7	2015	RESULTS: In human dermal microvascular endothelial cells, endothelin 1 induced phosphorylation of Fli-1 at Thr(312) through the sequential activation of c-Abl and protein kinase Cdelta, leading to a decrease in Fli-1 protein levels as well as a decrease in binding of Fli-1 to the target gene promoters, whereas bosentan treatment reversed those effects.	Bosentan	312-320	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	98-103